Adenosine and ischemic preconditioning

Curr Pharm Des. 1999 Dec;5(12):1029-41.

Abstract

Adenosine is released in large amounts during myocardial ischemia and is capable of exerting potent cardioprotective effects in the heart. Although these observations on adenosine have been known for a long time, how adenosine acts to achieve its anti-ischemic effect remains incompletely understood. However, recent advances on the chemistry and pharmacology of adenosine receptor ligands have provided important and novel information on the function of adenosine receptor subtypes in the cardiovascular system. The development of model systems for the cardiac actions of adenosine has yielded important insights into its mechanism of action and have begun to elucidate the sequence of signalling events from receptor activation to the actual exertion of its cardioprotective effect. The present review will focus on the adenosine receptors that mediate the potent anti-ischemic effect of adenosine, new ligands at the receptors, potential molecular signalling mechanisms downstream of the receptor, mediators for cardioprotection, and possible clinical applications in cardiovascular disorders.

Publication types

  • Review

MeSH terms

  • Adenosine / physiology*
  • Angioplasty, Balloon, Coronary / adverse effects
  • Animals
  • Clinical Trials as Topic
  • Coronary Artery Bypass / adverse effects
  • Heart / drug effects*
  • Humans
  • Ischemic Preconditioning, Myocardial / methods*
  • Ligands
  • Models, Cardiovascular
  • Myocardial Ischemia / pathology*
  • Purinergic P1 Receptor Agonists
  • Purinergic P1 Receptor Antagonists
  • Receptors, Purinergic P1 / physiology*
  • Signal Transduction
  • Vasodilator Agents / metabolism*

Substances

  • Ligands
  • Purinergic P1 Receptor Agonists
  • Purinergic P1 Receptor Antagonists
  • Receptors, Purinergic P1
  • Vasodilator Agents
  • Adenosine